Bolt Biotherapeutics, Inc. (BOLT)

NASDAQ: BOLT · IEX Real-Time Price · USD
1.400
+0.180 (14.75%)
At close: Mar 28, 2024, 4:00 PM
1.380
-0.020 (-1.43%)
After-hours: Mar 28, 2024, 6:46 PM EDT

Company Description

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer.

The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.

It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer.

The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F.

Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015.

Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics logo
Country United States
Founded 2015
IPO Date Feb 5, 2021
Industry Biotechnology
Sector Healthcare
Employees 100
CEO Dr. Randall C. Schatzman Ph.D.

Contact Details

Address:
900 Chesapeake Drive
Redwood City, California 94063
United States
Phone 650-665-9295
Website boltbio.com

Stock Details

Ticker Symbol BOLT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $20.00
CIK Code 0001641281
CUSIP Number 097702104
ISIN Number US0977021049
Employer ID 47-2804636
SIC Code 2834

Key Executives

Name Position
Dr. Randall C. Schatzman Ph.D. Chief Executive Officer and Director
Dr. Edgar George Engleman M.D. Founder and Independent Director
William P. Quinn Chief Financial Officer and Secretary
Grant Yonehiro C.F.A., M.B.A. Chief Business Officer
Dr. Edith A. Perez M.D. Chief Medical Officer
Wesley Burwell Vice President and Head of Human Resources
Dr. Nathan Ihle Ph.D. Senior Vice President of Pharmaceutical Operations

Latest SEC Filings

Date Type Title
Mar 21, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 21, 2024 10-K Annual Report
Mar 21, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 12, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Nov 9, 2023 10-Q Quarterly Report
Nov 9, 2023 8-K Current Report
Aug 7, 2023 10-Q Quarterly Report